Revenues and geographic information (Details 2) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 14,408
|
$ 14,054
|
$ 27,521
|
$ 27,287
|
| Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
3.00%
|
|
1.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
(2.00%)
|
|
| Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 11,781
|
|
$ 22,537
|
|
| Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
2.00%
|
|
1.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
(2.00%)
|
|
| Cardiovascular, renal and metabolic [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,688
|
2,655
|
$ 3,461
|
5,173
|
| Cardiovascular, renal and metabolic [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(36.00%)
|
|
(33.00%)
|
|
| Net sales, change in %, cc |
(37.00%)
|
|
(35.00%)
|
|
| Cardiovascular, renal and metabolic [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,181
|
2,357
|
$ 2,486
|
4,618
|
| Cardiovascular, renal and metabolic [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(50.00%)
|
|
(46.00%)
|
|
| Net sales, change in %, cc |
(51.00%)
|
|
(48.00%)
|
|
| Cardiovascular, renal and metabolic [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 480
|
298
|
$ 932
|
555
|
| Cardiovascular, renal and metabolic [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
61.00%
|
|
68.00%
|
|
| Net sales, change in %, cc |
59.00%
|
|
64.00%
|
|
| Cardiovascular, renal and metabolic [member] | Vanrafia [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 27
|
|
$ 43
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,181
|
|
$ 2,486
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(50.00%)
|
|
(46.00%)
|
|
| Net sales, change in %, cc |
(51.00%)
|
|
(48.00%)
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 480
|
|
$ 932
|
|
| Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
61.00%
|
|
68.00%
|
|
| Net sales, change in %, cc |
59.00%
|
|
64.00%
|
|
| Immunology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 2,780
|
2,549
|
$ 5,246
|
4,958
|
| Immunology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
6.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
3.00%
|
|
| Immunology [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,824
|
1,629
|
$ 3,390
|
3,163
|
| Immunology [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
12.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
10.00%
|
|
5.00%
|
|
| Immunology [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 550
|
477
|
$ 1,025
|
896
|
| Immunology [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
15.00%
|
|
14.00%
|
|
| Net sales, change in %, cc |
15.00%
|
|
13.00%
|
|
| Immunology [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 342
|
443
|
$ 730
|
899
|
| Immunology [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(23.00%)
|
|
(19.00%)
|
|
| Net sales, change in %, cc |
(25.00%)
|
|
(22.00%)
|
|
| Immunology [member] | Rhapsido [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 64
|
|
$ 101
|
|
| Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,824
|
|
$ 3,390
|
|
| Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
12.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
10.00%
|
|
5.00%
|
|
| Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 550
|
|
$ 1,025
|
|
| Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
15.00%
|
|
14.00%
|
|
| Net sales, change in %, cc |
15.00%
|
|
13.00%
|
|
| Immunology [member] | Top 20 products [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 342
|
|
$ 730
|
|
| Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(23.00%)
|
|
(19.00%)
|
|
| Net sales, change in %, cc |
(25.00%)
|
|
(22.00%)
|
|
| Neuroscience [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,877
|
1,457
|
$ 3,438
|
2,759
|
| Neuroscience [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
29.00%
|
|
25.00%
|
|
| Net sales, change in %, cc |
28.00%
|
|
22.00%
|
|
| Neuroscience [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,424
|
1,077
|
$ 2,588
|
1,976
|
| Neuroscience [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
31.00%
|
|
| Net sales, change in %, cc |
32.00%
|
|
29.00%
|
|
| Neuroscience [member] | Zolgensma Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 365
|
297
|
$ 667
|
624
|
| Neuroscience [member] | Zolgensma Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
23.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
20.00%
|
|
3.00%
|
|
| Neuroscience [member] | Aimovig [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 88
|
83
|
$ 183
|
159
|
| Neuroscience [member] | Aimovig [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
6.00%
|
|
15.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
8.00%
|
|
| Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,424
|
|
$ 2,588
|
|
| Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
31.00%
|
|
| Net sales, change in %, cc |
32.00%
|
|
29.00%
|
|
| Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 365
|
|
$ 667
|
|
| Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
23.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
20.00%
|
|
3.00%
|
|
| Oncology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 4,515
|
3,353
|
$ 8,536
|
6,236
|
| Oncology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
35.00%
|
|
37.00%
|
|
| Net sales, change in %, cc |
34.00%
|
|
34.00%
|
|
| Oncology [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,695
|
1,177
|
$ 3,211
|
2,133
|
| Oncology [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
44.00%
|
|
51.00%
|
|
| Net sales, change in %, cc |
43.00%
|
|
48.00%
|
|
| Oncology [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 651
|
454
|
$ 1,293
|
825
|
| Oncology [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
43.00%
|
|
57.00%
|
|
| Net sales, change in %, cc |
43.00%
|
|
55.00%
|
|
| Oncology [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 576
|
524
|
$ 1,133
|
1,016
|
| Oncology [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
12.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
6.00%
|
|
| Oncology [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 581
|
573
|
$ 1,074
|
1,125
|
| Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
1.00%
|
|
(5.00%)
|
|
| Net sales, change in %, cc |
0.00%
|
|
(7.00%)
|
|
| Oncology [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 562
|
298
|
$ 995
|
536
|
| Oncology [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
89.00%
|
|
86.00%
|
|
| Net sales, change in %, cc |
89.00%
|
|
85.00%
|
|
| Oncology [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 225
|
207
|
$ 436
|
400
|
| Oncology [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
8.00%
|
|
| Oncology [member] | Fabhalta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 225
|
120
|
$ 394
|
201
|
| Net sales, change in % |
88.00%
|
|
96.00%
|
|
| Net sales, change in %, cc |
88.00%
|
|
94.00%
|
|
| Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,695
|
|
$ 3,211
|
|
| Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
44.00%
|
|
51.00%
|
|
| Net sales, change in %, cc |
43.00%
|
|
48.00%
|
|
| Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 651
|
|
$ 1,293
|
|
| Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
43.00%
|
|
57.00%
|
|
| Net sales, change in %, cc |
43.00%
|
|
55.00%
|
|
| Oncology [member] | Top 20 products [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 576
|
|
$ 1,133
|
|
| Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
12.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
6.00%
|
|
| Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 581
|
|
$ 1,074
|
|
| Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
1.00%
|
|
(5.00%)
|
|
| Net sales, change in %, cc |
0.00%
|
|
(7.00%)
|
|
| Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 562
|
|
$ 995
|
|
| Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
89.00%
|
|
86.00%
|
|
| Net sales, change in %, cc |
89.00%
|
|
85.00%
|
|
| Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 225
|
|
$ 436
|
|
| Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
8.00%
|
|
| Oncology [member] | Top 20 products [member] | Fabhalta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 225
|
|
$ 394
|
|
| Oncology [member] | Top 20 products [member] | Fabhalta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
88.00%
|
|
96.00%
|
|
| Net sales, change in %, cc |
88.00%
|
|
94.00%
|
|
| Established Brands [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 3,548
|
4,040
|
$ 6,840
|
8,161
|
| Established Brands [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(12.00%)
|
|
(16.00%)
|
|
| Net sales, change in %, cc |
(14.00%)
|
|
(19.00%)
|
|
| Established Brands [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 302
|
303
|
$ 589
|
620
|
| Established Brands [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
(5.00%)
|
|
| Net sales, change in %, cc |
(1.00%)
|
|
(7.00%)
|
|
| Established Brands [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
191
|
$ 394
|
370
|
| Established Brands [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
6.00%
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
2.00%
|
|
| Established Brands [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 179
|
502
|
$ 363
|
1,048
|
| Established Brands [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(64.00%)
|
|
(65.00%)
|
|
| Net sales, change in %, cc |
(65.00%)
|
|
(66.00%)
|
|
| Established Brands [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 160
|
154
|
$ 310
|
304
|
| Established Brands [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
2.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
(2.00%)
|
|
| Established Brands [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 142
|
327
|
$ 297
|
704
|
| Established Brands [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(57.00%)
|
|
(58.00%)
|
|
| Net sales, change in %, cc |
(58.00%)
|
|
(59.00%)
|
|
| Established Brands [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 126
|
173
|
$ 230
|
362
|
| Established Brands [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(36.00%)
|
|
| Net sales, change in %, cc |
(30.00%)
|
|
(40.00%)
|
|
| Established Brands [member] | Myfortic [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 105
|
102
|
$ 216
|
201
|
| Established Brands [member] | Myfortic [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
3.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
0.00%
|
|
4.00%
|
|
| Established Brands [member] | Piqray/Vijoice [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 123
|
111
|
$ 204
|
211
|
| Established Brands [member] | Piqray/Vijoice [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
11.00%
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
10.00%
|
|
(4.00%)
|
|
| Established Brands [member] | Kymriah [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 88
|
99
|
$ 169
|
199
|
| Established Brands [member] | Kymriah [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(11.00%)
|
|
(15.00%)
|
|
| Net sales, change in %, cc |
(10.00%)
|
|
(16.00%)
|
|
| Established Brands [member] | Contract manufacturing [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 472
|
276
|
$ 824
|
619
|
| Established Brands [member] | Contract manufacturing [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
71.00%
|
|
33.00%
|
|
| Net sales, change in %, cc |
68.00%
|
|
27.00%
|
|
| Established Brands [member] | Other [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,660
|
1,802
|
$ 3,244
|
3,523
|
| Established Brands [member] | Other [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(8.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(11.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 302
|
|
$ 589
|
|
| Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
(5.00%)
|
|
| Net sales, change in %, cc |
(1.00%)
|
|
(7.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
|
$ 394
|
|
| Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
6.00%
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
2.00%
|
|
| Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 179
|
|
$ 363
|
|
| Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(64.00%)
|
|
(65.00%)
|
|
| Net sales, change in %, cc |
(65.00%)
|
|
(66.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 160
|
|
$ 310
|
|
| Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
2.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
(2.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 142
|
|
$ 297
|
|
| Established Brands [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(57.00%)
|
|
(58.00%)
|
|
| Net sales, change in %, cc |
(58.00%)
|
|
(59.00%)
|
|
| Established Brands [member] | Top 20 products [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 126
|
|
$ 230
|
|
| Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(36.00%)
|
|
| Net sales, change in %, cc |
(30.00%)
|
|
(40.00%)
|
|
| US |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 5,954
|
$ 6,249
|
$ 10,913
|
$ 11,961
|
| US | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
(9.00%)
|
|
| Net sales, change in %, cc |
(5.00%)
|
|
(9.00%)
|
|
| US | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 5,333
|
|
$ 9,792
|
|
| US | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(7.00%)
|
|
(10.00%)
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
|
|
$ 70
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
|
|
(97.00%)
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 214
|
|
$ 380
|
|
| US | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
55.00%
|
|
43.00%
|
|
| US | Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,069
|
|
$ 1,839
|
|
| US | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
16.00%
|
|
6.00%
|
|
| US | Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 315
|
|
$ 561
|
|
| US | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
17.00%
|
|
| US | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 942
|
|
$ 1,666
|
|
| US | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
28.00%
|
|
| US | Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 152
|
|
$ 269
|
|
| US | Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
58.00%
|
|
20.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,045
|
|
$ 1,970
|
|
| US | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
39.00%
|
|
47.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 493
|
|
$ 999
|
|
| US | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
38.00%
|
|
55.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 197
|
|
$ 367
|
|
| US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(20.00%)
|
|
(19.00%)
|
|
| US | Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 369
|
|
$ 655
|
|
| US | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
93.00%
|
|
90.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 163
|
|
$ 314
|
|
| US | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
9.00%
|
|
| US | Oncology [member] | Top 20 products [member] | Fabhalta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 124
|
|
$ 223
|
|
| US | Oncology [member] | Top 20 products [member] | Fabhalta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
63.00%
|
|
74.00%
|
|
| US | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 177
|
|
$ 339
|
|
| US | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
(12.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
|
|
$ 2
|
|
| US | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
|
|
(33.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 39
|
|
$ 64
|
|
| US | Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(83.00%)
|
|
(88.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 6
|
|
$ 16
|
|
| US | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(14.00%)
|
|
(20.00%)
|
|
| US | Established Brands [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 30
|
|
$ 58
|
|
| US | Established Brands [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(81.00%)
|
|
(84.00%)
|
|
| Rest of the world [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 8,454
|
|
$ 16,608
|
|
| Rest of the world [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
8.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
4.00%
|
|
| Rest of the world [member] | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 6,448
|
|
$ 12,745
|
|
| Rest of the world [member] | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
11.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
6.00%
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 1,183
|
|
$ 2,416
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
4.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
5.00%
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 266
|
|
$ 552
|
|
| Rest of the world [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
66.00%
|
|
90.00%
|
|
| Net sales, change in %, cc |
63.00%
|
|
83.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 755
|
|
$ 1,551
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
7.00%
|
|
9.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
3.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 235
|
|
$ 464
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
11.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
7.00%
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 342
|
|
$ 730
|
|
| Rest of the world [member] | Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(23.00%)
|
|
(19.00%)
|
|
| Net sales, change in %, cc |
(25.00%)
|
|
(22.00%)
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 482
|
|
$ 922
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
32.00%
|
|
36.00%
|
|
| Net sales, change in %, cc |
30.00%
|
|
31.00%
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 213
|
|
$ 398
|
|
| Rest of the world [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
6.00%
|
|
0.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
(6.00%)
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 650
|
|
$ 1,241
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
52.00%
|
|
56.00%
|
|
| Net sales, change in %, cc |
49.00%
|
|
49.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 158
|
|
$ 294
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
65.00%
|
|
63.00%
|
|
| Net sales, change in %, cc |
62.00%
|
|
55.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 576
|
|
$ 1,133
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
12.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
6.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 384
|
|
$ 707
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
17.00%
|
|
5.00%
|
|
| Net sales, change in %, cc |
15.00%
|
|
1.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 193
|
|
$ 340
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
80.00%
|
|
78.00%
|
|
| Net sales, change in %, cc |
82.00%
|
|
76.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 62
|
|
$ 122
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
10.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
5.00%
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Fabhalta [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 101
|
|
$ 171
|
|
| Rest of the world [member] | Oncology [member] | Top 20 products [member] | Fabhalta [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
130.00%
|
|
134.00%
|
|
| Net sales, change in %, cc |
130.00%
|
|
128.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 125
|
|
$ 250
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
6.00%
|
|
| Net sales, change in %, cc |
7.00%
|
|
2.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 191
|
|
$ 392
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
1.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
2.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 140
|
|
$ 299
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(49.00%)
|
|
(44.00%)
|
|
| Net sales, change in %, cc |
(50.00%)
|
|
(46.00%)
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 154
|
|
$ 294
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
5.00%
|
|
4.00%
|
|
| Net sales, change in %, cc |
3.00%
|
|
0.00%
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 112
|
|
$ 239
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(32.00%)
|
|
(31.00%)
|
|
| Net sales, change in %, cc |
(34.00%)
|
|
(34.00%)
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties |
$ 126
|
|
$ 230
|
|
| Rest of the world [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(36.00%)
|
|
| Net sales, change in %, cc |
(30.00%)
|
|
(40.00%)
|
|